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VARIATION IN USE OF $4 GENERIC PROGRAM AND POTENTIAL SAVINGS 
AMONG MEDICARE BENEFICIARIES--- 
 BIOSTATISTICS STUDENT’S INTERNSHIP EXIT REPORT 
Lei Zhou, M.S. 
University of Pittsburgh, 2010
 
As an option to fulfill the MS thesis requirement at the Department of Biostatistics, I worked as 
an intern under the supervision of Dr. Yuting Zhang at the Department of Health Policy & 
Management, Graduate School of Public Health, University of Pittsburgh, from January to June 
2010. During the internship, I have been fully involved in some of Dr. Zhang’s projects and have 
made the following contributions.  
First, I consolidated different pharmacy event data and medical claims data obtained from 
multiple sources into several analytic databases for those projects. The end products in this step 
included the analytic datasets, data dictionary for each corresponding dataset, and the SAS 
programming codes.   
After completion of the dataset construction, I had opportunities to fully apply the 
statistical skills I have learned during my coursework on a specific project, entitled “Variation in 
the use of $4 generic prescription and potential savings among Medicare beneficiaries.” Under 
the supervision of Dr. Zhang as well as collaborating with other colleagues, I played the leading 
role in data analysis, the interpretation of results and writing of a manuscript for publication. 
Public Health Relevance: Our research on these projects focused on evaluating the 
strengths and weaknesses of the Medicare prescription drug program, especially its effects on 
 iv 
vulnerable American populations such as under-served minorities, patients with severe mental 
health and multiple medical conditions. Through our research, public policy might be improved 
to eliminate health disparities in populations. Our findings from the project have important 
policy implications for optimizing cost-effective use of prescription plans to the public. 
Through this half-year long internship, I have had great opportunities to learn study 
design, data management, statistical analysis and hypothesis testing in a real world setting, to 
apply statistics/econometrics knowledge to large existing data, to evaluate the effects of health 
care policy and interventions on medical spending and health outcomes. In addition, I have 
practiced advanced SAS programming skills in manipulating the large datasets. 
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1.0  INTRODUCTION TO INTERNSHIP 
According to departmental degree requirements for the Master of Science, MS students could be 
permitted with approval of their primary advisors and the Biostatistics MS/MPH Program 
Committee to complete an internship as an option for fulfillment of the MS thesis requirement. 
By complying with this requirement, the purpose of this report is to explain what I did and 
learned during my internship under the supervision of Dr. Zhang, Yuting, at the Department of 
Health Policy and Management, Graduate School of Public Health, University of Pittsburgh, 
from January to June, 2010. 
During the internship period, I made two primary contributions. First, I assembled 
various analytic datasets for future analysis from the source data as well as the detailed data 
dictionary for each corresponding dataset, where the source data are obtained from multiple 
sources including pharmacy event data, medical claims data, census data, and drug database. I 
used PROC SQL language from SAS® 9.2 to manage and manipulate these large existing real-
world data (usually several hundred thousands or millions of observations). The description 
about the activities during this step is in Section 2.0 of this report. 
Following the completion of data construction, I moved onto the task of investigating the 
variation in the use of $4 generic prescriptions among Medicare beneficiaries, where I played a 
leading role in data analysis as a statistician, interpreting and publishing the results as a co-
author. The detailed results about this project are shown in Section 3.0 of this report. 
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2.0  DATA MANAGEMENT AND DATASET CONSTRUTION 
As an intern, I have been fully involved in several projects evaluating the strengths and 
weaknesses of the Medicare prescription drug program (a.k.a Medicare Part D), which was 
enacted as part of the Medicare Prescription Drug, Improvement, and Modernization Act MMA 
of 2003 (MMA, Section 101) and went into effect on January 1, 2006, to subsidize the costs of 
prescription drugs for Medicare beneficiaries in the United States. [1]  
In this first step of the internship, I identified those variables of interest which denoted 
the beneficiaries’ demography, socioeconomics, insurance status, medicine and medication uses, 
such as spending and counts, and drug information like name, strength, dosage form, and 
national drug code (NDC). These variables could be derived from various source data such as 
pharmacy event data and medical claims data obtained from the Centers for Medicare & 
Medicaid Services (CMS), census data obtained from the US Census 2000 database, area 
medical supply data obtained from Health Resources and Services Administration (HRSA), and 
drug information obtained from the First DataBank database  
Following the identification of these variables, I linked those source data through some 
specific identifiers and assembled the variables of interest from these source datasets into several 
analytic datasets for future analyses. In addition, I created a detailed data dictionary for each 
analytic dataset including the variable name, data type, and description. In this way, other 
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colleagues who would focus on some specific project in the future can easily find their needed 
variables by going through these dictionaries. 
Subsection 2.1 through 2.4 briefly described the source data we have been using, and in 
subsection 2.5, I showed an example to elaborate my activities on dataset construction. 
2.1 CMS-CCW SOURCE DATA 
CMS has contracted with the Buccaneer Computer Systems and Services, Inc. (BCSSI) to 
establish the Chronic Condition Data Warehouse (CCW).  The CCW contains existing CMS 
Medicare beneficiary claims data and are available for services beginning January 1, 1999 
through the most current year of Medicare data available, for a 5% random sample of Medicare 
beneficiaries. [1] 
The major data we used included the beneficiary annual summary file, Part D 
denominator file, Part D event data file and Part D plan characteristics file. The detailed 
guidelines for using these data and data descriptions can be found from the website 
of http://www.resdac.umn.edu . 
2.1.1 Beneficiary Annual Summary File 
The Beneficiary Annual Summary File, available and updated annually since 1999, 
contains demographic and enrollment information about each beneficiary enrolled in Medicare 
during a calendar year. For our current projects, we used the 2007 data. From this data, I 
identified the following variables: beneficiary unique identifier (bene_id), state and county codes 
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(state_cd, cnty_cd), ZIP code (bene_zip), date of birth (bene_dob), date of death (bene_dod), 
gender (sex), months of Part A/B/both A and B enrollment (a_mo_cnt, b_mo_cnt, ab_mo_cnt), 
months of Medicaid coverage (a.k.a. state buy-in coverage, buyin_mo),  months of managed care 
enrollment (hmo_mo) and Medicare status code (ms_cd) which can be used to define those who 
are disabled. The variables indicating different kinds of medical spending (inpatient, outpatient, 
nursing facility, physician visits, medical equipment, and hospice) and those 21 chronic 
conditions are also identified from this data. The complete definitions for these variables are 
shown in Appendix A. 
2.1.2 Medicare Part D Denominator File 
The denominator file, similar to the beneficiary annual summary file, available since 1999, also 
contains demographic and enrollment information about each beneficiary enrolled in Medicare 
during a calendar year. The variables I identified from 2007 data include the beneficiary unique 
identifier (bene_id), age (age), RTI (Research Triangle Institute) race (rti_race, which is more 
accurate than another race variable), months of Part D plan coverage (plncovmo), months of dual 
eligible (dual_mo, i.e., both Medicare and Medicaid coverage), monthly cost share group code 
(cstshr<mon#>, which can be used to determine the low-income subsidy status), monthly plan 
contract ID and benefit package ID (cntrct<mon#>, pbpid<mon#>). This file is not available 
after March of 2010 due to its incorporation into the beneficiary summary file since then. The 
data dictionary about this data is shown in Appendix B. 
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2.1.3 Medicare Part D Event Data File 
The PDE data are person-drug level claims data, containing prescription drug claims information 
for each beneficiary. From this source data, I identified the following variables: beneficiary 
unique identifier (bene_id), service provider ID (prvdr_id), prescriber ID (prscrbid), product 
service ID (prdsrvid), RX service date (srvc_dt), plan contract ID and benefit package ID 
(plncntrc, plnpbprc), days of supply (dayssply), drug coverage status code (drcvstcd),  all kinds 
of drug costs (totalcst, ptpayamt, lics_amt, othtroop, cpp_amt, npp_amt), benefit phase of the 
Part D event (bnftphas). The detailed explanation about these variables is shown in Appendix C. 
2.1.4 Medicare Part D Plan Characteristics File 
Each state may have its own types of prescription plans based on the standard Medicare Part D 
benefit design. The plan characteristics file contains all the information for each specific Part D 
prescription plan. The variables we used include plan contract ID and benefit package ID 
(cntrctid, plan_id), drug benefit type (drgbentp), type of gap coverage (gapcovtp), deductible 
amount (ded_amt),  how initial coverage limit is defined (icl_app), ICL amount (icl_amt). The 
complete data dictionary is shown in Appendix D. 
2.2 FIRST DATABANK SOURCE DATA 
First DataBank, a subsidiary of Hearst Corporation, is the leading provider of electronic drug 
information to the healthcare industry. We obtained the drug information data from their most 
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widely used drug database, First DataBank’s National Drug Data File Plus (NDDF Plus), which 
combines a comprehensive set of drug database elements, drug pricing and clinical information 
with multiple types of unique drug identifiers.  
After carefully reading the NDDF Plus documentation, I extracted those data from the 
database, which include the following drug information: NDC number (ndc), drug dosage form 
(gcdf_desc), drug strength (str60), package size (ps), generic name (gnn60), brand name (bn), 
multiple source indicators (ndcgi1, gcnseq_gi), generic indicator (gni), enhanced therapeutic 
classifications (etc_id, etc_name). And then I linked these data through those specific drug 
identifiers to consolidate those variables into one dataset.  
The therapeutic classification is complicated to define. The enhanced therapeutic 
classification system was designed using a parent-to-child relationship hierarchy, i.e., for some 
etc_id’s, they identify the therapeutic classifications that are at the most top of the hierarchy, and 
for some etc_id’s, they are related to these parent id’s and identify a low-level classification 
associated to their parent levels. So for our convenience, I separated these parent-to-child 
hierarchy etc_id’s into several single-level classification id’s, such as top level (tc_1), second 
level (tc_2), and third level (tc_3) and so on to the eighth level (tc_8). 
The detailed variable description is shown in Appendix E, and the entity relationship 
diagrams of these datasets are shown in Figure 1. 
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Figure 1. Entity relationship diagram of First DataBank Source Data 
2.3 U.S. CENSUS DATA, AREA SUPPLY DATA AND ZIP-HRR DATA 
2.3.1 U.S. Census 2000 Data 
U.S. Census 2000 Data can be downloaded from the website of U.S. Census Bureau 
(http://factfinder.census.gov/servlet/DownloadDatasetServlet?_lang=en). We used the data 
coming from the Summary File 3 (SF3) database, which consists of 813 detailed tables regarding 
the social, economic and housing characteristics information in Census 2000 data compiled from 
a sample of approximately 19 million housing units that received the Census 2000 long-form 
questionnaire. SF3 presents data for the United States, the 50 States, the District of Columbia and 
Puerto Rico in a hierarchical sequence down to the block group for many tabulations, from 
which we used the 860 ZIP-code level data to obtain the total population, population for each 
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race/ethnic group, population for each gender, population for each age group, population below 
the poverty line, household income information, household income for different race/ethnic 
group, employment and education information. 
I downloaded the tables including above variables from SF3 database, then imported 
them into SAS and linked them together through the ZIP-code. 
2.3.2 Area Medical Supply Data 
For the area medical supply data, the source data can be downloaded from the website of 
Health Resources and Services Administration (HRSA). The following datasets were mainly 
used:   
1). Physician Characteristics 2006 data, derived from 2006 American Medical 
Association Physician Master file (AMA MF), which provides the characteristics of primary care 
physicians (family physicians, general internists, and pediatricians), specialists, obstetricians 
/gynecologists  at ZIP-code level. 
2). Health Professional Shortage Area (HPSA) and Medically Underserved 
Areas/Medically Underserved Populations (MUA/P) file linked to ZIP-codes, from which 
researchers could obtain the information about the percentage of 2006 estimated population 
living in 2007 Primary Care HPSA at ZIP-code level. 
2.3.3 Zip-HRR Mapped Data 
These data can be downloaded from the Dartmouth Atlas of Health Care. The ZIP-code to 
Hospital Referral Region (HRR) crosswalk file allows researchers to aggregate data at the ZIP-
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code level to HRR level. The future analysis on the geographic variation in medication uses 
would be primarily focused on HRR level. 
2.3.4 Data Merging and Creating Segregation Index 
After obtaining the above mentioned source data, I merged the census data, area medical supply 
data and ZIP-HRR mapped data through the unique ZIP-code into one consolidated dataset, 
which contained all the variables of interest mentioned above. These variables can be adjusted as 
covariates for future analysis on variation in medication uses. 
Another important factor that can be adjusted as a covariate is the index of dissimilarity 
or segregation, i.e., the segregation of African American or Hispanic to Non Hispanic White, 
which was calculated based on HRR level. The following equation was employed to calculate 
the index,[2] 
D = 0.5 * ∑ ฬ
௉୧ౘ/౞
௉್/೓
െ ௉୧౭
௉ೢ
ฬ , where 
ܲ
/௛ is the total Black or Hispanic population in each HRR area 
iୠ/୦ is the Black or Hispanic population in census tract i (ZIP-code area) 
௕ܲ
i୵ is the non-Hispanic White population in census tract i (ZIP-code area) ܲ
௪ܲ is the total non- Hispanic White population in each HRR area  
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2.4 CMS-HCC/RXHCC RISK SCORES 
The CMS Hierarchical Condition Categories (HCC) and Prescription Drug Hierarchical 
Condition Categories (RxHCC) models are implemented to adjust Medicare capitation payments 
to health care plans for the health and prescription expenditure risk of their enrollees. These risk 
scores are also considered as important covariates in our future variation analysis. 
The CMS website (https://www.cms.gov/) provides HCC and RxHCC software to be 
downloaded to calculate these risk scores. For example, the HCC software includes a SAS 
program that calls several SAS macros to create HCC score variables using coefficients from 
different regression models. 
2.5 EXAMPLE OF DATASET CONSTRUCTION---DONUT HOLE STUDY 
After obtaining all of above source data, I began to assemble data to create the final analytic 
dataset for each project. I took one of the ongoing projects, the “donut hole” study, as an 
example to show how these source data can be linked together to construct analytic data. 
2.5.1 Introduction to “Donut Hole” 
The standard benefit that Part D plans offer is defined in terms of the benefit structure, which 
may vary by year. In 2007, this benefit required a $265 deductible, and the beneficiary paid 25% 
of the cost of covered Part D prescription drugs up to an initial coverage limit of $2,400. [3] 
Once the initial coverage limit was reached, the beneficiary entered into the Coverage Gap 
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period, more commonly referred to as the “Donut Hole”, in which they paid the full cost of their 
prescriptions up to $5,451 in total, i.e. their true out-of-pocket expenditures (TrOOP) on 
formulary drugs for this year reached $3,800, which is the sum of the deductible, initial 
copayment before “donut hole” threshold, and payment in coverage gap. After this second 
threshold, the beneficiary entered into the catastrophic coverage phase, in which they only paid 
5% coinsurance and the plan paid the rest 95% in excess of $5,451. [3] The standard benefit 
design is shown below in Figure 2.  
This project mainly applied the pre-post comparison methods on existing large healthcare 
data to investigate the inferable causality between Part D policy interventions and its health 
outcomes, especially the effects of the “Donut Hole” for vulnerable American populations such 
as under-served minorities, patients with severe mental health and multiple medical conditions, 
i.e., the racial/ethnic disparity or geographic variations in use of different medications and 
medical care services before and after the “Donut Hole” was under investigation.  
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 Figure 2. Standard Medicare Prescription Drug Benefit Design, 2007 
2.5.2 Selection criteria 
In this study, we wanted to investigate the variation on medication uses, comparing before and 
after donut-hole period information. The study population was identified from the beneficiary 
annual summary file as well as the Part D denominator file. I linked these two files together 
through the unique beneficiary identifier (bene_id) to form a consolidated file, on which the 
selection criteria were implemented, 
1) Beneficiary still alive (bene_dod with missing value); 
2) 12-month continuous enrollment in both Part A and B program (ab_mo_cnt = 12); 
3) 12-month continuous enrollment in Part D program (plncovmo = 12); 
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4) No managed care or non-fee-for-service coverage in any month (hmo_mo = 0); 
5) All in stand-alone Part D plans (the first letter of each month’s contract ID is ‘S’, i.e., 
CNTRCT<mon#> = “S”) 
2.5.3 Defining outcome variable and other covariates variables  
Following the above step, the study population was determined. The outcome variable and 
covariates were defined next. As we investigated the variation on medication uses as well as the 
pre- and post- donut hole information, the first thing was to define the pre- and post- donut hole 
period, and next summarize the drug spending and counts for each beneficiary during these two 
periods. To fulfill this approach, I linked the Part D event data with above defined study sample 
through the beneficiary identifier (bene_id) to get all drug claims for each beneficiary in the 
study sample. Then I identified those drug events in the phases that covered the “donut hole” 
(bnftphas = ‘DI’, ‘DC’, ‘PI’, ‘PC’, ‘II’, ‘IC’, ‘CC’) or catastrophic period (bnftphas = ‘DC’, 
‘PC’, ‘IC’, ‘CC’), and then created two indicators to describe whether or not each drug event was 
in the “Donut Hole” or catastrophic phase, where if the drug event’s phase was in those phases, 
the indicator would be assigned a value of ‘1’. After that, I defined the first date triggering the 
“Donut Hole” or catastrophic period, which was the same with the earliest prescription date 
(srvc_dt) in these periods for each beneficiary. Once obtaining these information, I moved onto 
summarizing the person-level total and monthly averaged drug spending and counts for pre- and 
post- donut hole period respectively. 
I created the outcome variables, drug spending and counts, for each beneficiary in the 
study sample. Next, I linked other source data with the study sample to add some other 
covariates, e.g., linking with Part D plan characteristics file through contract ID (cntrctid) and 
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benefit package ID (plan_id) to add deductible amount (ded_amt), initial coverage limit type 
(icl_app), initial coverage limit amount (icl_amt), drug benefit type (drgbentp), gap coverage 
type (gapcovtp); linking with CMS-HCC/RxHCC risk score files through beneficiary identifier 
(bene_id)  to add these two types of risk score; linking with census-area supply data to add HRR 
number, segregation indices through beneficiary’s ZIP-code. 
The entity relationship diagrams of these datasets are shown in Figure 3. 
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Figure 3. Entity relationship diagram of “Donut Hole” Study 
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2.6 CONCLUSIONS 
During my internship, I served as Data Manager, SAS programmer and Statistician. As data 
manager and SAS programmer, I was responsible for maintaining and manipulating the source 
data, creating analytic datasets from the source data, and generating detailed readable data 
dictionaries for each dataset I have created. I have not only practiced my skills in advanced SAS 
programming language, but also improved my ability to keep things in an organized way. For 
example, when I wrote the SAS code, I always kept in mind to put comments as much as 
possible. In this way, people including me, could easily go back to the codes to check the 
problems or repeat the procedures. Another example is that I generated an Excel log file to 
record the information for each dataset I have created, including the updated date, source data I 
have used, the description of the new dataset, the purpose of this dataset and the SAS codes to 
creating it. In this way, people can easily find the dataset they want and understand how the 
dataset was constructed. 
When calculating the segregation index and generating the HCC and RxHCC risk 
scores, I worked as a statistician. I conducted online literature searches to find references on how 
to calculate the segregation index and figure out what methods those references have used. I 
made decisions on what method I should use to calculate the index. For the risk scores, I read 
carefully the software documentation to understand what regression models they are using to 
calculate the scores and what the purpose of each step is when the software calls those SAS 
macros. In this way, I was able to function independently. 
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3.0  VARIATION IN USE OF $4 GENERIC PROGRAM AND POTENTIAL SAVINGS 
AMONG MEDICARE PART D BENEFICIARIES 
Spending for prescription drugs in US is rising. It was $234.1 billion in 2008 and $216 .7 billion 
in 2006, nearly 6 times the $40 billion spent in 1990. [4] Generic drugs are typically less 
expensive than brand-name drugs, and prices for generics have historically increased less than 
those for brand-name drugs. [4-6] The U.S. Food and Drug Administration (FDA) examines the 
generic formulations and approves them as bioequivalent to brand-name drugs in safety and 
quality.[7] Therefore, use of generic formulation instead of a brand-name for multisource drug 
(i.e., those with more than one generic available) could be one potential strategy for limiting drug 
expenditures.  
Wal-Mart first launched a highly-discounted drug program in 2006, which is called $4 
Prescription Program and covers a 30-day generic prescription at $4 or a 90-day generic 
prescription at $10.[8] Then during the following years several retail stores, like Target, Giant 
Eagle, Walgreen, and CVS, launched their own low-cost generic programs which are quite 
similar to Wal-Mart’s $4 program and the number of covered generic drugs keeps increasing to 
above 400 (can be seen from the $4 prescriptions lists from the websites of those retailers). 
Nowadays, due to the low cost and easy access to these low-cost programs, we could assume a 
huge amount of potential savings on the medication spending for the nation. However, we could 
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find no existing investigation about the exact potential savings as these low-cost programs are 
relatively new to the society.  
We used the 2007 Medicare Part D data and First DataBank data to identify those who 
ever used at least one drug that were commonly available from the Wal-Mart $4 and then 
estimated potential savings by switching prescriptions to $4 programs among those who paid 
more than $4 per 30 days for these drugs. Also we investigated the variation in use of these $4 
drugs to see if the beneficiaries’ insurance status, demography, living area (i.e., urban or rural, 
the distance to the closest Wal-Mart pharmacy store) and other factors could affect the likelihood 
of use of these drugs. 
3.1 METHODS 
3.1.1 Data 
Wal-Mart first launched this low-cost generic program to the nation in 2006, and the number of 
$4 generics in the lists from 2006 to 2009 didn’t change dramatically. Only a slight increase can 
be seen. And we compared the $4 generic lists from Wal-Mart with other pharmacy retailers as 
well, and found the similarities among them. Thus we used the latest updated 2009 list to 
determine which drugs are available through the $4 program. For the current analysis, we 
focused on those in tablet and capsule forms, which is easy to calculate the drug use and 
spending. 
First DataBank data contain complete drug information, such as NDC number, brand 
name, equivalent generic name, strength, dosage form, package size, generic or brand indicator, 
and the therapeutic class. We matched this data with Wal-Mart’s $4 list by drug name to identify 
all NDC’s that are available from Wal-Mart’s $4 program list. 
For drug spending and counts, we used 2007 Medicare Part D event data and matched 
them with above matched NDC data through drugs’ NDC number. In this way, we obtained the 
drug expenditure information for all NDC’s that are available in Wal-Mart’s $4 program list. 
In the end, we merged this drug information data with the “donut hole” study sample 
through the beneficiaries identifier and thus, identified all those 2007 Medicare Part D 
beneficiaries who ever used the Wal-Mart’s $4 program drugs. The final data was based on drug 
claim level. 
3.1.2 Study population 
3.1.2.1 Drug Claims 
For all the drug claims, we separated them into three sub-groups,  
1) All claims that were probably filled through $4 program: beneficiaries paid $4 for 30-
day or $10 for 90-day and they have no other plan payments or federal low-income-subsidy 
(LIS) or other public assistance subsidy, i.e., the total drug cost was just the $4 program cost;  
2) All claims that were considered as potential savings by switching to $4 program: 
beneficiaries paid more than $4 program cost, thus they could save by switching their 
prescriptions to $4 program, and Medicare plans, LIS, and public subsidy would also save by 
such switching because they would not pay anymore;  
3) All claims that were not considered as potential savings: beneficiaries paid less than $4 
program cost because Medicare plans, LIS, and public subsidy covered most part of the drug 
costs, thus they have no incentives to switch to $4 program.  
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Among each sub-group, we identified those brand-name claims as well as generic claims.  
3.1.2.2 Subjects 
We assigned the beneficiaries to two sub-groups, 
1) Those filled at least one claim through $4 program, no matter if they paid greater or 
less than $4 for their other claims. We considered them as current users.  
2) Those filled at least one potential saving claim, but excluding those who also filled at 
least one claim through $4 program or those subsidized by LIS. We considered the second sub-
group as non-users.  
We compared the demography between current users and non-users to see if the use of $4 
program varies significantly. 
3.1.3 Potential savings 
We calculated three parts of potential savings among the second sub-group of claims.  
First, we calculated the potential savings by switching from regular generic to the $4 
program. In this way, the beneficiary would pay $4 for 30-day or $10 for 90-day, and the plan 
and public subsidy would not pay anymore. 
Second, we calculated the potential savings by switching from brand name to the $4 
program, which was similar to the savings in first part. The calculations for these two parts are as 
following,  
  Total saving = ∑ ሺܶ݋ݐ݈ܽ ݀௔௟௟ ௖௟௔ ݎݑ݃ ܿ݋ݏݐ െ $4 ݌ݎ݋݃ݎܽ݉ ܿ݋ݏݐሻ௜௠௦  
  Beneficiaries saving =  ∑ ݅ܽݎݕᇱݏ ܿ݋݌ܽݕ݉݁݊ݐ െ $4 ݌ݎ݋݃ݎܽ݉ ܿ݋ݏݐሻ 
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ሺܤ݂݁݊݁݅ܿ௔௟௟ ௖௟௔௜௠௦
  Plan saving = ∑ ሺ ݈ܲܽ݊ ݌ܽݕ݉݁݊ݐሻ௔௟௟ ௖௟௔௜௠௦  
  Public Subsidy saving = ∑ ሺ ܲݑܾ݈݅ܿ ݏݑܾݏ݅݀݅݁ݏ ݌ܽݕ݉݁݊ݐሻ௔௟௟ ௖௟௔௜௠௦  
Last part, we calculated the potential savings by switching from brand name to regular 
generic. We calculated this part of savings because it might not be feasible and available to the 
society if everyone switches to $4 program. This calculation was based on drug level. First we 
calculated the per 30-day average drug cost for each generic drug. Then using these per 30-day 
average costs and the days of supply of the brand version drugs, we estimated their total costs 
assuming they were switched to their corresponding regular generic versions. In this way, we 
estimated the savings from brand name to regular generics. However, this estimation was based 
on drug level; thus, we ould not c  estimate the person level average saving. 
Total saving = ∑  ሼ ܶ݋ݐ݈ܽ ݀ݎݑ݃ ܿ݋ݏݐ ݂݋ݎ ܾݎܽ݊݀ ݊ܽ݉݁ ݀ݎݑ݃ െ௔௟௟ ௗ௥௨௚௦  ሺ݌݁ݎ 30 െ
݀ܽݕ ܿ݋ݏݐ ݂݋ݎ ݈ܽݐ݁ݎ݊ܽݐ݅ݒ݁ ݃݁݊݁ݎ݅ܿ ݀ݎݑ݃ כ ሺ݀ܽݕݏ ݋݂ ݏݑ݌݌݈ݕ ݂݋ݎ ܾݎܽ݊݀ ݊ܽ݉݁ሻ/30ሽ 
For those claims in the third sub-group, the beneficiaries received subsidies and therefore 
paid less than $4 for these drugs, they would not have the incentives to use this $4 program. We 
only calculated the potential savings from the perspectives of Medicare plan and other public 
subsidies. 
3.1.4 Variation in use of $4 generic program 
By applying the chi-square test and the t-test, we compared the demographic factors between the 
current users and the non-users to check what kind of population could be more or less likely to 
use this $4 program. 
As Wal-Mart is the first national store that offered this $4 program since 2006, we 
assumed that majority of the users in our data (year of 2007) obtained the access to $4 program 
from Wal-Mart. In this case, we calculated the distance for each beneficiary to the closest Wal-
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Mart based on their ZIP-code of residence. This calculation was accomplished by using the 
ArcGIS software. We obtained the longitude and latitude information for each Wal-Mart store 
around the United States as well as for the center of each ZIP-code area. Then by using the 
ArcGIS software, we calculated the distance from the center of each ZIP-code area to its closest 
Wal-Mart store. Those beneficiaries who lived in the same ZIP-code area have the same distance. 
Then by fitting a logistic regression model, we checked the likelihood of using $4 program 
among different levels of multiple factors including this distance. Then we checked the residuals, 
outliers and goodness-of-fit for the model. 
3.2 RESULTS 
3.2.1 Summary of Prescription Claims among Medicare Part D Beneficiaries 
We found that (shown in Table 1), in 2007 there were totally 9,918,962 claims for 106 kinds of 
drugs that were commonly available from Wal-Mart’s $4 program, filled by 595,693 Medicare 
beneficiaries. 
Among these claims, only 9.8% of them were filled through 76 kinds of brand-name 
drugs by 22.1% of the sampled beneficiaries, and the rest were filled through 103 kinds of 
generic drugs by 98.6% of the beneficiaries. The beneficiaries overlapped between these two 
kinds of claims because one beneficiary could fill multiple prescription claims. 
Among these brand-name drug claims, about 48% of them were filled with beneficiary’s 
copayment greater than $4 program cost (i.e., $4 for 30-day, $10 for 90-day), thus they were 
considered as potential saving claims. And 51% of claims were filled with beneficiary’s 
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copayment less than $4 program cost due to the subsidies by LIS or other public assistance 
programs. We excluded this part from the calculation of potential savings because of lack of 
incentives to switch to $4 program.  
Among the generic drug claims, only 24.7% could be considered as potential saving 
claims, and the rest were excluded from the calculation of potential savings because they were 
subsidized by LIS (73%) or they were filled through the $4 program (2.3%).  
 
Table 1. Summary of Prescription Claims among Medicare Part D Beneficiaries 
 
# of 
Claims 
# of 
Beneficiary* 
% of  
total 
claims 
% of  
Beneficiary
% of  
brand name 
claims 
% of 
generic 
claims 
# of 
drugs 
Total Claims 9,918,962 595,693 - - - - 106 
Brand-name Claims 972,103 131,812  9.8 22.1 - - 76 
Not using $4, 
could save 
465,218 73,776 4.7 12.4 47.9 - 75 
Copayment ≤ $4 496,363 74,650 5.0 12.5 51.1 - 74 
Generic Claims 8,946,859 587,357 90.2 98.6 - - 103 
Not using $4, 
could save 
2,212,048 244,550 22.3 41.1 - 24.7 102 
Copayment ≤ $4 6,528,304 478,510 65.8 80.3 - 73.0 103 
Currently using $4 206,507 33,840 2.1 5.7 - 2.3 101 
*The numbers don’t add up because one beneficiary could fill multiple claims. 
3.2.2 Demography of study population 
Table 2 shows that 33,840 beneficiaries were defined as current users and 270,918 were defined 
as non-users. Compared to non-users, current users were more likely to be white (92.5% vs. 
91.7%, p<0.0001), younger (72.7±8.6 vs. 74.1±9.0, p<0.0001), younger than 74 (59.8% vs. 
53%, p<0.0001), live outside of the urban area (59.5% vs. 67.1%, , p<0.0001) and having 4 or 
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more chronic conditions (21.9% vs 21.1%, p=0.0005). The significant p-values are most likely 
due to the large sample size of the two populations. 
Table 2. Demography of study population 
 Non-users 
(270,918) 
Current users
(33,840) 
p-value* 
Female (%) 62.6 63.0 0.147 
Race (%)   <0.0001 
White 91.7 92.5 <0.0001 
Black 3.9 3.8 0.380 
Hispanic 2.5 2.4 0.265 
Asian 1.1 0.7 <0.0001 
Native 0.2 0.2 0.240 
Metropolitan Area (%) 67.1 59.5 <0.0001 
Age Group (%)   <0.0001 
<65 6.8 8.9 <0.0001 
65-74 46.2 50.9 <0.0001 
75-84 34.3 31.9 <0.0001 
85-99 12.7 8.3 <0.0001 
Chronic Conditions (%)   <0.0001 
                              0 13.4 12.6 <0.0001 
1-3 65.5 65.5 0.982 
4 or more 21.1 21.9 0.0005 
Age (Mean±STD) 74.1±9.0 72.7±8.6 <0.0001 
Risk Score (Mean±STD) 0.89±0.29 0.92±0.29 <0.0001 
 
3.2.3 Potential Savings 
Table 3 and Table 4 show that if all generic potential saving claims switch to $4 generic claims, 
the total annual saving and beneficiaries’ saving would be $17,591,736 and be $6,949,582, 
respectively by 244,550 beneficiaries. And corresponding per person savings would be $71.94 
(95% CI, $71.51-$72.36) and $28.42 (95% CI, $28.25-$28.58). Only part of these people had 
Medicare plan payment and public subsidy for their prescriptions, the total plan savings would 
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be $10,466,366 and the public subsidy saving would be $150,074 by 164,403 beneficiaries; per 
person saving would be $63.66 (95% CI, $63.20-$64.12) and $31.34 (95% CI, $29.84-$32.84), 
respectively. 
For brand-name potential saving claims, if they switch to $4 generic claims, the total 
annual saving would be $19,780,945 by 73,776 beneficiaries, and per person saving would be 
$268.12 (95% CI, $265.52-$270.73). And the total beneficiaries’ saving would be $7,793,562; 
per person saving would be $105.64 (95% CI, $104.50-$106.78). Only part of these people had 
Medicare plan payment and public subsidy for their prescriptions, the total plan savings would 
be $9,804,742 by 43,989 beneficiaries; per person saving would be $222.90 (95% CI, $220.43-
$225.36), and the public subsidy saving would be $2,151,831 by 10,548 beneficiaries; per person 
saving would be $204 (95% CI, $199.77-$208.24). 
Totally, if all potential saving claims switch to $4 generic program regardless of brand-
name claims or generic claims, the total and beneficiaries’ annual savings would be $37,372,680 
and $14,743,144 by 267,285 beneficiaries, and per person saving would be $139.82 (95% CI, 
$138.88-140.77) and $55.16 (95% CI, $54.75-$55.56), respectively. And the plan saving would 
be $20,271,109 by 185,017 beneficiaries; per person saving would be $109.56 (95% CI, 
$108.74-$110.39). For public subsidy, the total savings would be $2,301,905 by 14,471 
beneficiaries; per person saving would be $159.07 (95% CI, $155.67-$162.47).  
In addition, we estimated the potential savings for switching the brand-name claims to 
regular generic claims, because sometimes it’s not quite reasonable and feasible for all brand-
name claims to be switched to the $4 generic claims. In this case, the total and beneficiaries’ 
annual savings would be $14,414,229 and $5,506,894, and the plan saving would be $6,849,071, 
and the public subsidy saving would be $2,043,624. These savings were estimated based on drug 
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levels instead of person levels which has been discussed in method section, thus per person 
savings were not estimated. 
Table 3. Summary of Potential Savings 
 Total  
Saving 
Beneficiary  
Saving 
Plan  
Saving 
Public Subsidies 
Saving 
# of 
Beneficiaries 
From regular to $4 
generic1 
$17,591,736 $6,949,582 $10,466,366 $150,074 244,550  
From brand name 
to $4 generic2 
$19,780,945 $7,793,562 $9,804,742 $2,151,831 73,776  
Total saving to $4 
generic* 
$37,372,680 $14,743,144 $20,271,109 $2,301,905 267,285 
From brand name 
to regular generic3 
$14,414,229  $5,506,894  $6,849,071  $2,043,624  73,776  
* = 1 + 2 
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Table 4. Summary of Potential Savings (Per person) 
 Total 
Saving 
Beneficiary 
Saving 
Plan 
Saving 
Public Subsidies 
Saving 
From regular generic 
to $4 generic 
$71.94 
($71.51-$72.36) 
$28.42 
($28.25-$28.58) 
$63.66  
($63.20-$64.12) 
(n=164,403) 
$31.34  
($29.84-$32.84) 
(n=4,789) 
From brand name to 
$4 generic 
$268.12 
($265.52-$270.73) 
$105.64 
($104.50-$106.78)
$222.90 
($220.43-$225.36) 
(n=43,989) 
$204.00  
($199.77-$208.24) 
(n=10,548) 
Total saving to $4 
generic 
$139.82 
($138.88-140.77) 
$55.16 
($54.75-$55.56) 
$109.56 
 ($108.74-$110.39)  
(n=185,017) 
$159.07 
($155.67-$162.47) 
(n=14,471) 
 
For those beneficiaries who received federal LIS or other public subsidies, they paid less 
than $4 for most of their claims; they would not have incentives to switch themselves. We only 
calculated the total cost of these claims as well as their copayments, payment by the plans and 
public subsidies, which is shown in Table 5. For those generic claims, the plans paid 
$34,410,710 in a year for 478,510 beneficiaries, and public subsidies paid $22,443,909. And for 
those brand name claims, the plans paid $8,794,458 in a year for 74,650 beneficiaries, and public 
subsidies paid $8,212,482. However, if these brand name claims switch to the regular generic 
claims, the plans could still save $5,085,988 in total, and public subsidies would save $5,684,736 
in total. 
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Table 5. Summary of Spending for those with federal or public assistance 
 Total  
Cost 
Beneficiary 
Copayment 
Plan  
Payment 
Public Subsidies 
payment 
# of 
Beneficiaries 
Generic claims $64,678,548  $7,751,557  $34,410,710  $22,443,909  478,510  
Brand name 
claims 
$17,827,548  $796,694  $8,794,458  $8,212,482  74,650  
Total  $82,506,096  $8,548,251  $43,205,168  $30,656,391  483,541  
Saving from 
brand name to 
regular generic 
$11,049,040  $263,699  $5,085,988  $5,684,736  74,650  
 
3.2.4 Variation in use of $4 program 
To investigate the variation in use of $4 program, we fitted logistic regression models, modeling 
on the probability of using $4 program. For the response variable, we created an indicator for the 
current users with value of ‘1’ versus the non-users with value of ‘0’. And the potential 
explanatory variables identified from our data included demography factors (age, gender, and 
race), geographic residence information (metropolitan area indicator, distance to the closest Wal-
Mart), socioeconomic information (percentage of poor within each ZIP-code area, percentage of 
who ever finished high school within each ZIP-code area), medical conditions (disabled 
indicator, number of chronic conditions, risk scores). The model is expressed as 
Logit(p) = log(p/1-p) = α + β’x 
where p denotes the response probability to use $4 program, and α is the intercept 
parameter and β is the vector of slope parameters. 
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We applied the stepwise selection method (Hosmer and Lemeshow, 2000) to choose the 
important variables. The p-value for variable entry was set at 0.15 and that for variable removal 
was set at 0.2 to obtain a continued “significant “contribution.[9] The Hosmer-Lemeshow test for 
goodness-of-fit model check was applied after selection of variables.  
The results are shown in Table 6, all the variables were important and included in the 
model. Table 7 shows that for per 5 years older, the beneficiary is 10% less likely to use the $4 
program (OR = 0.9, 95% CI, 0.89-0.91). A woman is 4% more likely to use the $4 program than 
a man, holding other variables the same. (OR = 1.04, 95% CI, 1.01-1.06). For those who live in 
rural area, per 5 miles further to Wal-Mart store, they are 14% less likely to use the $4 program 
(OR = 0.86, 95% CI, 0.85-0.87); and per 10 miles further, 26% less likely to use (OR = 0.74, 
95% CI, 0.72-0.75). For those live in metropolitan area, per 5 miles further to Wal-Mart store, 
they are 23% less likely to use the $4 program (OR = 0.77, 95% CI, 0.75-0.79); and per 10 miles 
further, 41% less likely to use (OR = 0.59, 95% CI, 0.57-0.62). Asian (OR = 0.71, 95% CI, 0.62-
0.82) and black (OR = 0.83, 95% CI, 0.78-0.88) people are less likely to use than white people, 
while Hispanic (OR = 1.13, 95% CI, 1.04-1.22) are more likely to use. Other results are shown in 
Table 7 as well. 
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 Table 6. Estimated coefficient of logistic model 
Effect Coefficients Std p 
Age -0.0207    0.001 <.0001
Female (vs. Male) 0.0182     0.006 0.0041
Distance -0.0303     0.001  <.0001
Metropolitan area (vs. Rural area) -0.1192     0.009  <.0001
Distance*Metropolitan -0.0217     0.002  <.0001
Race (vs. White)    
Black -0.08      0.044  0.0684 
Hispanic 0.226     0.049  <.0001
Asian -0.235      0.070  0.0008
American Native 0.102      0.118  0.3880 
Percentage of poor 0.019     0.001  <.0001
Percentage of who finished high school 0.029     0.001  <.0001
Number of chronic conditions 0.017     0.004  <.0001
Disabled (vs. Non Disabled) -0.097      0.014  <.0001
Risk score 0.312     0.025  <.0001
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 Table 7. Estimated odds ratio (OR) for each variable in the logistic model 
Effect Estimated OR
95% CI 
Lower limit 
95% CI 
Upper limit
Age (per 5 years older) 0.902 0.894       0.909 
Female (vs. Male) 1.037 1.012       1.063 
Metropolitan area (vs. Rural area) 0.788 0.761       0.816 
Distance  (per 5 miles further, rural area) 0.860 0.851       0.868 
Distance  (per 10  miles further, rural area) 0.739 0.724       0.754 
Distance  (per 5 miles further, metropolitan area) 0.771 0.754 0.788 
Distance  (per 10  miles further, metropolitan area) 0.594 0.569 0.621 
Race (vs. Wihte)    
Black vs. White 0.828 0.777 0.883 
Hispanic vs. White 1.125 1.038 1.219 
Asian vs. White 0.709 0.616 0.816 
American Native vs. White 0.993 0.764 1.292 
Percentage of poor 1.020 1.018       1.021 
Percentage of who finished high school 1.030 1.028       1.031 
Number of chronic conditions 1.018 1.009       1.026 
Disabled (vs. Non disabled) 0.824 0.779       0.872 
Risk score 1.366 1.301       1.434 
 
The Hosmer-Lemeshow test (Table 8) shows that this model did not fit adequately 
(p<0.05). However, from the residual plots, we could find only few outliers, which indicated that 
the model fitted well. The plots are shown in Appendix F. 
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 Table 8. Hosmer-Lemeshow Goodness-of-Fit Test 
Group Total Observed 
Events 
Expected  
Events 
Observed  
Non Events 
Expected  
Non Events 
1 28865 1065 1163.618236 27800 27701.38176 
2 28866 1891 1902.842473 26975 26963.15753 
3 28865 2336 2342.766745 26529 26522.23326 
4 28865 2716 2697.854664 26149 26167.14534 
5 28865 2977 3019.489509 25888 25845.51049 
6 28866 3330 3328.505112 25536 25537.49489 
7 28868 3763 3654.818949 25105 25213.18105 
8 28865 4160 4030.171422 24705 24834.82858 
9 28865 4515 4518.410484 24350 24346.58952 
10 28857 5411 5505.506005 23446 23351.49399 
Chi-square DF p-value 
20.1475  8 0.0098 
 
Distance and percentage of poor and percentage of who finished high school were 
calculated based on ZIP-code level, i.e., for those beneficiaries lived in the same ZIP-code area, 
they have the same information of these three variables. Thus there is a correlated data issue. We 
applied the GEE model with repeated measures to treat ZIP-code area as a cluster. The estimated 
coefficients for each variable are shown in Table 9. We found that most  of the estimated 
coefficients are similar to those in the above model, which is probably because of the large 
number of clusters (28,956 ZIP-codes) with small number of observations (0 to 258) in each 
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cluster, as well as the very small working correlation which is 0.00002. The GEE fit criteria 
(QIC) is about 195831, which is huge and not supporting the adequate model fit. 
Table 9. Estimated Coefficients of GEE Model 
Effect Coefficients Std p 
Age -0.0207 0.001 <.0001 
Female (vs. Male) 0.0359 0.0125 0.0042 
Distance -0.0303 0.0015 <.0001 
Metropolitan area (vs. Rural area) -0.240 0.0272 <.0001 
Distance*Metropolitan -0.0216 0.0038 <.0001 
Race (vs. White)    
Black -0.189 0.0364 <.0001 
Hispanic 0.117 0.0442 0.0079 
Asian -0.344 0.0880 <.0001 
American Native -0.395 0.1059 0.0002 
Percentage of poor 0.019 0.0013 <.0001 
Percentage of who finished high school 0.029 0.0010 <.0001 
Number of chronic conditions 0.017 0.004 <.0001 
Disabled (vs. Non Diabled) -0.195 0.029 <.0001 
Risk score 0.313 0.024 <.0001 
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3.3 DISCUSSIONS 
We found that in 2007, among those beneficiaries taking the drugs available from $4 generic 
program, only 5.7% of them (33,840 out of 595,693) actually filled their prescriptions through 
this program, which accounted for only 2% of the total prescription claims in the year. And 45% 
of the beneficiaries (267,285 out of 595,693) could potentially save $37,372,680 in total and 
$139.82 per person (95%CI, $138.88-$140.77) by switching their prescriptions to $4 generic 
program. As the data we used was only 5% sample of total Medicare beneficiaries, the total 
potential savings would probably be much more than this amount. 
For our current analysis, we assumed these beneficiaries filled their prescriptions through 
Wal-Mart because Wal-Mart first offered this program since 2006 and our analysis was based on 
2007 data. In fact, it is not quite reasonable or feasible for all the beneficiaries to go to Wal-Mart 
to fill their prescriptions. We can verify this later when the new pharmacy data are available in 
near future, which would indicate where they filled their prescriptions.  In that case, we need to 
recalculate the distance from their residence area to the stores where they actually filled the 
prescriptions. 
For the variation in use of $4 generic program, we found younger people and women are 
more likely to use this program. Further distance to Wal-Mart can reduce the likelihood of use. 
Black and Asian people are less likely to use compared with white people, while Hispanic are 
more likely to use. In addition, in area with higher percentage of poor or higher percentage of 
who finished high school, people are more likely to use this program. Our findings reinforce the 
importance of understanding the drivers of variation in use of $4 program. Both areal-level 
variation and patient characteristics could potentially affect the use of $4 program. These 
findings may offer us an opportunity to gain insight into the potential for public policy actions to 
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improve the value of the health care delivered in the United States. In future analysis, we need to 
investigate more factors, like beneficiaries’ insurance status, access to other retail stores. 
In conclusion, at present, the $4 program is still new to both patients and healthcare 
providers who know little about it. Patients, especially those without insurance or those with low 
income, could get great benefit from this highly discounted program to lower their high costs on 
medications. In addition, our research intended to remind the healthcare providers of these low-
cost prescription programs. It is quite helpful for physicians to get familiar with these programs 
and provide these options to their patients to help ease their financial burden from taking 
medications.  
4.0  SUMMARY OF INTERNSHIP 
During my internship, I acted as data manager, programmer and statistician. I played a leading 
role on a small piece of project, which has provided me great opportunity to learn how to be fully 
involved into a research project, how to think and resolve problem independently, how to write 
up a research paper and how to deal with multiple tasks to meet the deadline. I also obtained 
great opportunity to apply my statistical knowledge in a real-world setting.  
I hope my experience in this student internship is helpful for those MS student who wish 
to fulfill their degree requirements through this option. 
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APPENDIX A: 
 
DATA DICTIONARY OF BENEFICIARY ANNUAL SUMMARY FILE 
Variable Data Type Description 
BENE_ID Char Encrypted 723 Beneficiary ID 
STATE_CD Char State code (SSA) 
CNTY_CD Char County code (SSA) 
BENE_ZIP Char Zip code of residence 
METRO Char Metro Status 
SEX Char Sex 
BENE_DOB Num Date of birth (Date) 
BENE_DOD Num Date of death (Date) 
MS_CD Char Medicare status code 
A_MO_CNT Num Number of Months enrolled in Part A 
B_MO_CNT Num Number of Months enrolled in Part B 
AB_MO_CNT Num Number of Months enrolled in both Part A and B 
HMO_MO Num Number of non Fee-for-Service Months 
BUYIN_MO Num Number of Months Medicaid Coverage 
MEDREIMB_IP Num Inpatient annual Medicare reimbursement amount 
BENRES_IP Num Inpatient annual beneficiary responsibility amount 
PPPYMT_IP Num Inpatient annual primary payer reimbursement amount 
MEDREIMB_SN
F 
Num Skill Nursing Facility annual Medicare reimbursement amount 
BENRES_SNF Num Skill Nursing Facility annual beneficiary responsibility amount 
PPPYMT_SNF Num Skill Nursing Facility annual primary payer reimbursement amount 
MEDREIMB_OP Num Outpatient Institutional annual Medicare reimbursement amount 
BENRES_OP Num Outpatient Institutional annual beneficiary responsibility amount 
PPPYMT_OP Num Outpatient Institutional annual primary payer reimbursement amount 
MEDREIMB_CA
R 
Num Carrier annual Medicare reimbursement amount 
BENRES_CAR Num Carrier annual beneficiary responsibility amount 
PPPYMT_CAR Num Carrier annual primary payer reimbursement amount 
MEDREIMB_D
ME 
Num Durable Medical Equipment annual Medicare reimbursement amount 
BENRES_DME Num Durable Medical Equipment annual beneficiary responsibility amount 
PPPYMT_DME Num Durable Medical Equipment annual primary payer reimbursement amount 
MEDREIMB_H
H 
Num Home Health Agency annual Medicare reimbursement amount 
PPPYMT_HH Num Home Health Agency annual primary payer reimbursement amount 
MEDREIMB_HS Num Hospice annual Medicare reimbursement amount 
BENRES_HS Num Hospice annual beneficiary responsibility amount 
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Variable Data Type Description 
PPPYMT_HS Num Hospice annual primary payer reimbursement amount 
IPSTY Num Annual number of Inpatient admissions in calendar year 
OPVST Num Annual number of Outpatient Institutional visits in calendar year 
SNF_COVDYS Num Annual number of Skill Nursing Facility covered days in calendar year 
PHSVST Num Annual number of physician office visits in calendar year 
AMI Num Chronic Condition Warehouse: Acute Myocardial Infarction 
ALZH Num Chronic Condition Warehouse: Alzheimer`s Disease 
ALZHDMTA Num Chronic Condition Warehouse: Alzheimer`s Disease and Related Disorders or Senile 
ATRIALFB Num Chronic Condition Warehouse: Atrial Fibrillation 
CATARACT Num Chronic Condition Warehouse: Cataract 
CHRNKIDN Num Chronic Condition Warehouse: Chronic Kidney Disease 
COPD Num Chronic Condition Warehouse: Chronic Obstructive Pulmonary Disease 
CHF Num Chronic Condition Warehouse: Heart Failure 
DIABETES Num Chronic Condition Warehouse: Diabetes 
GLAUCOMA Num Chronic Condition Warehouse: Glaucoma 
HIPFRAC Num Chronic Condition Warehouse: Hip/Pelvic Fracture 
ISCHMCHT Num Chronic Condition Warehouse: Ischemic Heart Disease 
DEPRESSN Num Chronic Condition Warehouse: Depression 
OSTEOPRS Num Chronic Condition Warehouse: Osteoporosis 
RA_OA Num Chronic Condition Warehouse: RA/OA 
STRKETIA Num Chronic Condition Warehouse: Stroke / Transient Ischemic Attack 
CNCRBRST Num Chronic Condition Warehouse: Female Breast Cancer 
CNCRCLRC Num Chronic Condition Warehouse: Colorectal Cancer 
CNCRPRST Num Chronic Condition Warehouse: Prostate Cancer 
CNCRLUNG Num Chronic Condition Warehouse: Lung Cancer 
CNCRENDM Num Chronic Condition Warehouse: Endometrial Cancer 
AMIE Num Earliest indication of Acute Myocardial Infarction (Date) 
ALZHE Num Earliest indication of Alzheimer`s Disease (Date) 
ALZHDMTE Num Earliest indication of Alzheimer`s Disease and Related Disorders  
ATRIALFE Num Earliest indication of Atrial Fibrillation (Date) 
CATARCTE Num Earliest indication of Cataract (Date) 
CHRNKDNE Num Earliest indication of Chronic Kidney Disease (Date) 
COPDE Num Earliest indication of Chronic Obstructive Pulmonary Disease (Date) 
CHFME Num Earliest indication of Heart Failure (Date) 
DIABTESE Num Earliest indication of Diabetes (Date) 
GLAUCMAE Num Earliest indication of Glaucoma (Date) 
HIPFRACE Num Earliest indication of Hip/Pelvic Fracture (Date) 
ISCHMCHE Num Earliest indication of Ischemic Heart Disease (Date) 
DEPRSSNE Num Earliest indication of Depression (Date) 
OSTEOPRE Num Earliest indication of Osteoporosis (Date) 
RA_OA_E Num Earliest indication of RA/OA (Date) 
STRKTIAE Num Earliest indication of Stroke / Transient Ischemic Attack (Date) 
CNCRBRSE Num Earliest indication of Female Breast Cancer (Date) 
CNCRCLRE Num Earliest indication of Colorectal Cancer (Date) 
CNCRPRSE Num Earliest indication of Prostate Cancer (Date) 
CNCRLNGE Num Earliest indication of Lung Cancer (Date) 
CNCENDME Num Earliest indication of Endometrial Cancer (Date) 
BASF_YR_NUM Char BASF Year 
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APPENDIX B:  
 
DATA DICTIONARY OF PART D DENOMINATOR FILE 
Variable Data Type Description 
BENE_ID Char Encrypted 723 Beneficiary ID 
STATE_CD Char SSA State Code 
CNTY_CD Char SSA County Code 
BENE_ZIP Char Zip Code of Residence 
BENE_DOB Num Date of Birth 
SEX Char Sex 
AGE Num Age at Beginning of Bene Enrollment 
MS_CD Char Medicare Status Code 
BUYIN01 Char Jan. Medicare Entitlement/Buy-In Indicator 
BUYIN02 Char Feb. Medicare Entitlement/Buy-In Indicator 
BUYIN03 Char Mar. Medicare Entitlement/Buy-In Indicator 
BUYIN04 Char Apr. Medicare Entitlement/Buy-In Indicator 
BUYIN05 Char May Medicare Entitlement/Buy-In Indicator 
BUYIN06 Char Jun. Medicare Entitlement/Buy-In Indicator 
BUYIN07 Char Jul. Medicare Entitlement/Buy-In Indicator 
BUYIN08 Char Aug. Medicare Entitlement/Buy-In Indicator 
BUYIN09 Char Sep. Medicare Entitlement/Buy-In Indicator 
BUYIN10 Char Oct. Medicare Entitlement/Buy-In Indicator 
BUYIN11 Char Nov. Medicare Entitlement/Buy-In Indicator 
BUYIN12 Char Dec. Medicare Entitlement/Buy-In Indicator 
HMOIND01 Char Jan. HMO Indicator 
HMOIND02 Char Feb. HMO Indicator 
HMOIND03 Char Mar. HMO Indicator 
HMOIND04 Char Apr. HMO Indicator 
HMOIND05 Char May HMO Indicator 
HMOIND06 Char Jun. HMO Indicator 
HMOIND07 Char Jul. HMO Indicator 
HMOIND08 Char Aug. HMO Indicator 
HMOIND09 Char Sep. HMO Indicator 
HMOIND10 Char Oct. HMO Indicator 
HMOIND11 Char Nov. HMO Indicator 
HMOIND12 Char Dec. HMO Indicator 
CNTRCT01 Char Jan. Encrypted Contract ID 
CNTRCT02 Char Feb. Encrypted Contract ID 
CNTRCT03 Char Mar. Encrypted Contract ID 
CNTRCT04 Char Apr. Encrypted Contract ID 
CNTRCT05 Char May Encrypted Contract ID 
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Variable Data Type Description 
CNTRCT06 Char Jun. Encrypted Contract ID 
CNTRCT07 Char Jul. Encrypted Contract ID 
CNTRCT08 Char Aug. Encrypted Contract ID 
CNTRCT09 Char Sep. Encrypted Contract ID 
CNTRCT10 Char Oct. Encrypted Contract ID 
CNTRCT11 Char Nov. Encrypted Contract ID 
CNTRCT12 Char Dec. Encrypted Contract ID 
PBPID01 Char Jan. Encrypted Plan Benefit Package ID 
PBPID02 Char Feb. Encrypted Plan Benefit Package ID 
PBPID03 Char Mar. Encrypted Plan Benefit Package ID 
PBPID04 Char Apr. Encrypted Plan Benefit Package ID 
PBPID05 Char May Encrypted Plan Benefit Package ID 
PBPID06 Char Jun. Encrypted Plan Benefit Package ID 
PBPID07 Char Jul. Encrypted Plan Benefit Package ID 
PBPID08 Char Aug. Encrypted Plan Benefit Package ID 
PBPID09 Char Sep. Encrypted Plan Benefit Package ID 
PBPID10 Char Oct. Encrypted Plan Benefit Package ID 
PBPID11 Char Nov. Encrypted Plan Benefit Package ID 
PBPID12 Char Dec. Encrypted Plan Benefit Package ID 
CSTSHR01 Char Jan. Cost Share Group Code 
CSTSHR02 Char Feb. Cost Share Group Code 
CSTSHR03 Char Mar. Cost Share Group Code 
CSTSHR04 Char Apr. Cost Share Group Code 
CSTSHR05 Char May Cost Share Group Code 
CSTSHR06 Char Jun. Cost Share Group Code 
CSTSHR07 Char Jul. Cost Share Group Code 
CSTSHR08 Char Aug. Cost Share Group Code 
CSTSHR09 Char Sep. Cost Share Group Code 
CSTSHR10 Char Oct. Cost Share Group Code 
CSTSHR11 Char Nov. Cost Share Group Code 
CSTSHR12 Char Dec. Cost Share Group Code 
HMO_MO Char HMO Coverage Count 
BUYIN_MO Char State Buy-In Coverage Count 
PLNCOVMO Char Plan Coverage Months Number 
DUAL_MO Char Dual Eligible Months Number 
RTI_RACE Char RTI (Research Triangle Institute) Race C 
BENEDPSQ Num BENE_ID w/ More than One Record 
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APPENDIX C: 
 
DATA DICTIONARY OF PART D EVENT DATA 
Variable Data Type Description 
BENE_ID Char Encrypted 723 Beneficiary ID Number 
SRVC_DT Num RX Service Date (DOS) 
PRVDR_ID Char Service Provider ID 
PRSCRBID Char Prescriber ID 
PRDSRVID Char Product Service ID 
PLNCNTRC Char Plan Contract Record ID 
PLNPBPRC Char Plan PBP Record Number 
QTYDSPNS Num Quantity Dispensed 
DAYSSPLY Num Days of Supply 
FILL_NUM Num Fill Number 
DRCVSTCD Char Drug Coverage Status Code: 
     C = Covered 
     E = Supplemental drugs 
     O = Over-the-counter drug 
PTPAYAMT Num Patient Pay Amount 
OTHTROOP Num Other TrOOP Amount 
LICS_AMT Num Low Income Cost Sharing Subsidy Amount ( 
CPP_AMT Num Covered D Plan Paid Amount (CPP) 
NPP_AMT Num Non-Covered Plan Paid Amount (NPP) 
TOTALCST Num Gross Drug Cost 
BNFTPHAS Char The benefit phase of the Part D Event 
     Blank = not a covered drug 
     DD = Deductible phase 
     DP = Deductible to Pre-ICL 
     DI = Deductible to ICL (Coverage Gap) 
     DC = Deductible to Catastrophic 
     PP = Pre-ICL phase 
     PI = Pre-ICL to ICL 
     PC = Pre-ICL to Catastrophic 
     II = ICL (Coverage Gap) phase 
     IC = ICL to Catastrophic 
     CC = Catastrophic       
TIER_ID Char Medicare Part D formulary tier identifier 
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DATA DICTIONARY OF PLAN CHARACTERISTICS FILE 
Variable Data Type Description 
CNTRCTID Char Encrypted Contract ID 
PLAN_ID Char Encrypted Plan ID 
DRGBENTP Char Drug Benefit Type 
   1 = Defined Standard Benefit 
   2 = Actuarially Equivalent Standard 
   3 = Basic Alternative 
   4 =Enhanced Alternative 
GAPCOVTP Char Type of gap coverage offered 
DED_APP Char How Deductible is applied: 1-Medicare Defined; 2-Plan Defined; 3-No Deductible 
DED_AMT Num Deductible Amt. 
ICL_APP Char How ICL is applied: 1-Medicare Defined; 2-Plan Defined; 3-No ICL 
ICL_AMT Num ICL Amt. 
OOPT_AMT Num OOP Threshold Amt. 
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APPENDIX E: 
 
DATA DICTIONARY OF FIRST DATABANK DATA 
Variable Data Type Description 
NDC Char NDC 
BN Char Brand Name 
GNN60 Char Generic Name 
GNI Char Generic Name Indicator:  
     0 = Non-drug Item;  
     1 = Generically Named;  
     2 = Brand Named 
STR60 Char Drug Strength Description 
GCDF_DESC Char Dosage Form Code Description 
PS Num Package Size 
ETC_NAME Char ETC Therapeutic Class Description 
TC_1 Char Top level ETC Class 
TC_2 Char 2nd level ETC Class 
TC_3 Char 3rd level ETC Class 
TC_4 Char 4th level ETC Class 
TC_5 Char 5th level ETC Class 
TC_6 Char 6th level ETC Class 
TC_7 Char 7th level ETC Class 
TC_8 Char 8th level ETC Class 
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APPENDIX F:  
 
MODEL DIAGNOSTICS PLOTS FOR LOGISTIC REGRESSION 
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